Show simple item record

dc.contributor.advisorHansen, John-Bjarne
dc.contributor.advisorBrækkan, Sigrid
dc.contributor.authorPaulsen, Benedikte
dc.date.accessioned2024-06-05T07:33:51Z
dc.date.available2024-06-05T07:33:51Z
dc.date.issued2019-06-03
dc.description.abstractBackground: Venous thromboembolism (VTE) represents a significant burden of health for those affected, and complications after a VTE are especially pronounced in cancer patients. One fifth of all cancer patients will develop a VTE during their disease. Routine primary thrombophylaxis is not recommend in ambulatory cancer patients due to lack of tools to identify those at especially high risk, as anticoagulants comes with a substantial risk of major bleeding. Aim: The aim was to perform a systematic literature search to gather existing information, summarize and evaluate the evidence on prediction models for VTE in ambulatory cancer patients. Methods: Published scientific articles were obtained by systematically searching the Medline and Embase databases, and in addition, a free-text search in PubMed was applied to ensure optimal coverage of the search. Results: A total of 22 articles on risk assessment models (RAMs) in ambulatory cancer patients was identified, of these 9 papers presented novel models and the rest validated one or more RAM. The identified scores were the Khorana risk score (2008), Vienna CATS score (2010), Protect score (2012), CONKO score (2013), ThroLy score (2016), ONKOTEV score (2017), COMPASS-CAT score (2017), Tic-onco index (2018) and Vienna nomogram (2018). The Khorana risk score has been validated the vast majority of the identified studies, with main critique is that >50% of patients fall into an intermediate risk category. Further, The Vienna CATS, Protecht, CONKO, COMPASS-CAT and Vienna nomogram has been externally validated and showed somewhat varying results. Conclusion: Several RAMs on cancer-related thromboembolism in ambulatory cancer patients are developed. Although promising performance is found for many of the scores, most validation studies are of suboptimal quality, and the clinical feasibility of the models are yet to be established. Additionally, continuously effort is needed to address the bleeding risk in this patient group.en_US
dc.identifier.urihttps://hdl.handle.net/10037/33748
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2019 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)en_US
dc.subject.courseIDMED-3950
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Hematologi: 775en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Hematology: 775en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleRisk assessment models for prediction of venous thromboembolism in ambulatory cancer patients – A literature reviewen_US
dc.typeMaster thesisen_US
dc.typeMastergradsoppgaveen_US


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)